Hope for Alzheimer’s. Safety in Science.
A new generation of amyloid immunotherapy: effective, reduced adverse effects, and designed for real-world care.
ABOUT US
Pioneering Safer Alzheimer’s Therapy
Alzora Bio is a research group at the University of Southampton developing a next-generation amyloid antibodies for Alzheimer’s disease. Our therapy is designed to reduce harmful brain plaques while lowering the risk of serious side effects like brain swelling and microbleeds (ARIA), a common issue with current treatments.
By improving safety, we aim to reduce the need for costly monitoring, support clinician confidence, and help patients maintain quality of life for longer. We are developing a disease-modifying therapy for Alzheimer’s disease that aims to optimize both efficacy and tolerability.
THE CHALLENGE
Barriers to Widespread Use of Alzheimer’s Antibody Treatments
Approved Antibody Therapies
FDA and MHRA have approved amyloid antibodies that slow Alzheimer’s progression by targeting toxic proteins in the brain.
Limited Adoption
Despite proven clinical benefit, these therapies are not widely used in clinical practice.
High Drug Costs
The therapies are expensive, making them difficult to justify for long-term or large-scale use.
Expensive Safety Monitoring
MRI scans are required to monitor side effects, adding cost and burden to healthcare systems.
Share Your Perspective on Alzheimer’s Treatment
We’re gathering feedback from patients, carers, clinicians, and health professionals to help shape the future of safer, more effective Alzheimer’s therapies.
Choose the survey that best fits your experience below – your voice matters.
Understanding Our Approach
OUR SOLUTION
Innovating for Better Outcomes
We have engineered clinically tested antibodies that effectively clear disease-causing amyloid from the brain with less inflammation and fewer side effects.
By selectively targeting the receptors involved in amyloid clearance, our therapy reduces the risk of inflammation, microbleeds, and brain swelling. With longer circulation time, fewer doses are needed easing the treatment burden.
This approach means less intensive monitoring, helping to reduce costs and improve quality of life for patients, carers, and healthcare systems.
Targeted amyloid clearance
Reduced inflammation
Less frequent dosing
Lower monitoring burden
Support That Brings Hope Home
Helping people live longer, fuller lives with safer Alzheimer’s treatment.
Confidence in Care Decisions
A safer, evidence-based therapy clinicians can trust and manage with ease.
Designed for Real-World Health Systems
Reduces treatment burden and monitoring costs at scale.
A Smarter Path to Collaboration
Next-gen antibodies built for integration, safety, and scale.
GET IN TOUCH
Contact us for any inquiries or assistance
Whether you’re a patient, carer, clinician or partner, we’d love to connect and hear your thoughts.